A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Article Details
- CitationCopy to clipboard
Jones P, Altamura S, De Francesco R, Paz OG, Kinzel O, Mesiti G, Monteagudo E, Pescatore G, Rowley M, Verdirame M, Steinkuhler C
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
J Med Chem. 2008 Apr 24;51(8):2350-3. doi: 10.1021/jm800079s. Epub 2008 Mar 28.
- PubMed ID
- 18370373 [ View in PubMed]
- Abstract
Histone deacetylase (HDAC) inhibitors offer a promising strategy for cancer therapy, and the first generation HDAC inhibitors are currently in the clinic. Entirely novel ketone HDAC inhibitors have been developed from the cyclic tetrapeptide apicidin. These compounds show class I subtype selectivity and levels of cellular activity comparable to clinical candidates. A representative example has demonstrated tumor growth inhibition in a human colon HCT-116 carcinoma xenograft model comparable to known inhibitors.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Vorinostat Histone deacetylase 1 IC 50 (nM) 30 8 37 Details Vorinostat Histone deacetylase 2 IC 50 (nM) 82 8 37 Details Vorinostat Histone deacetylase 3 IC 50 (nM) 57 8 37 Details Vorinostat Histone deacetylase 6 IC 50 (nM) 43 7.5 37 Details